Literature DB >> 8755514

RNA binding by the Wilms tumor suppressor zinc finger proteins.

A Caricasole1, A Duarte, S H Larsson, N D Hastie, M Little, G Holmes, I Todorov, A Ward.   

Abstract

The Wilms tumor suppressor gene WT1 is implicated in the ontogeny of genito-urinary abnormalities, including Denys-Drash syndrome and Wilms tumor of the kidney. WT1 encodes Kruppel-type zinc finger proteins that can regulate the expression of several growth-related genes, apparently by binding to specific DNA sites located within 5' untranslated leader regions as well as 5' promoter sequences. Both WT1 and a closely related early growth response factor, EGR1, can bind the same DNA sequences from the mouse gene encoding insulin-like growth factor 2 (Igf-2). We report that WT1, but not EGR1, can bind specific Igf-2 exonic RNA sequences, and that the zinc fingers are required for this interaction. WT1 zinc finger 1, which is not represented in EGR1, plays a more significant role in RNA binding than zinc finger 4, which does have a counterpart in EGR1. Furthermore, the normal subnuclear localization of WT1 proteins is shown to be RNase, but not DNase, sensitive. Therefore, WT1 might, like the Kruppel-type zinc finger protein TFIIIA, regulate gene expression by both transcriptional and posttranscriptional mechanisms.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8755514      PMCID: PMC38785          DOI: 10.1073/pnas.93.15.7562

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence.

Authors:  F J Rauscher; J F Morris; O E Tournay; D M Cook; T Curran
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

2.  Characterization of the zinc finger protein encoded by the WT1 Wilms' tumor locus.

Authors:  J F Morris; S L Madden; O E Tournay; D M Cook; V P Sukhatme; F J Rauscher
Journal:  Oncogene       Date:  1991-12       Impact factor: 9.867

3.  Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter.

Authors:  D A Melton; P A Krieg; M R Rebagliati; T Maniatis; K Zinn; M R Green
Journal:  Nucleic Acids Res       Date:  1984-09-25       Impact factor: 16.971

4.  Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping.

Authors:  M Gessler; A Poustka; W Cavenee; R L Neve; S H Orkin; G A Bruns
Journal:  Nature       Date:  1990-02-22       Impact factor: 49.962

5.  Evolution of insulin-like growth factor II: characterization of the mouse IGF-II gene and identification of two pseudo-exons.

Authors:  P Rotwein; L J Hall
Journal:  DNA Cell Biol       Date:  1990-12       Impact factor: 3.311

6.  Developmentally programmed induction of differentiation inhibiting activity and the control of stem cell populations.

Authors:  P D Rathjen; J Nichols; S Toth; D R Edwards; J K Heath; A G Smith
Journal:  Genes Dev       Date:  1990-12       Impact factor: 11.361

7.  Transcriptional repression mediated by the WT1 Wilms tumor gene product.

Authors:  S L Madden; D M Cook; J F Morris; A Gashler; V P Sukhatme; F J Rauscher
Journal:  Science       Date:  1991-09-27       Impact factor: 47.728

8.  Alternative splicing and genomic structure of the Wilms tumor gene WT1.

Authors:  D A Haber; R L Sohn; A J Buckler; J Pelletier; K M Call; D E Housman
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

9.  Modulation of DNA binding specificity by alternative splicing of the Wilms tumor wt1 gene transcript.

Authors:  W A Bickmore; K Oghene; M H Little; A Seawright; V van Heyningen; N D Hastie
Journal:  Science       Date:  1992-07-10       Impact factor: 47.728

10.  DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations.

Authors:  M Little; G Holmes; W Bickmore; V van Heyningen; N Hastie; B Wainwright
Journal:  Hum Mol Genet       Date:  1995-03       Impact factor: 6.150

View more
  43 in total

1.  Loss of FBP function arrests cellular proliferation and extinguishes c-myc expression.

Authors:  L He; J Liu; I Collins; S Sanford; B O'Connell; C J Benham; D Levens
Journal:  EMBO J       Date:  2000-03-01       Impact factor: 11.598

2.  Molecular basis for modulation of biological function by alternate splicing of the Wilms' tumor suppressor protein.

Authors:  J H Laity; H J Dyson; P E Wright
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

Review 3.  The possible role and application of WT1 in human leukemia.

Authors:  Z Chen
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

4.  Altered expression of the WT1 wilms tumor suppressor gene in human breast cancer.

Authors:  G B Silberstein; K Van Horn; P Strickland; C T Roberts; C W Daniel
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

5.  Vascular endothelial growth factor (VEGF) is suppressed in WT1-transfected LNCaP cells.

Authors:  Kylie Graham; Wenliang Li; Bryan R G Williams; Gail Fraizer
Journal:  Gene Expr       Date:  2006

6.  Wilms Tumor Suppressor, WT1, Cooperates with MicroRNA-26a and MicroRNA-101 to Suppress Translation of the Polycomb Protein, EZH2, in Mesenchymal Stem Cells.

Authors:  Murielle M Akpa; Diana Iglesias; LeeLee Chu; Antonin Thiébaut; Ida Jentoft; Leah Hammond; Elena Torban; Paul R Goodyer
Journal:  J Biol Chem       Date:  2015-12-10       Impact factor: 5.157

7.  WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes.

Authors:  R C Davies; C Calvio; E Bratt; S H Larsson; A I Lamond; N D Hastie
Journal:  Genes Dev       Date:  1998-10-15       Impact factor: 11.361

8.  Par4 is a coactivator for a splice isoform-specific transcriptional activation domain in WT1.

Authors:  D J Richard; V Schumacher; B Royer-Pokora; S G Roberts
Journal:  Genes Dev       Date:  2001-02-01       Impact factor: 11.361

9.  The Wilms' tumor 1 (WT1) gene (+KTS isoform) functions with a CTE to enhance translation from an unspliced RNA with a retained intron.

Authors:  Yeou-cherng Bor; Jennifer Swartz; Avril Morrison; David Rekosh; Michael Ladomery; Marie-Louise Hammarskjöld
Journal:  Genes Dev       Date:  2006-05-31       Impact factor: 11.361

10.  RNA Binding by the KTS Splice Variants of Wilms' Tumor Suppressor Protein WT1.

Authors:  Tadateru Nishikawa; Jonathan M Wojciak; H Jane Dyson; Peter E Wright
Journal:  Biochemistry       Date:  2020-09-29       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.